- Home
- NRIX vs MGTX Comparison
NRIX vs MGTX Comparison
Compare NRIX & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- MGTX
- Stock Information
- Founded
- NRIX 2009
- MGTX 2015
- Country
- NRIX United States
- MGTX United States
- Employees
- NRIX N/A
- MGTX N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRIX Health Care
- MGTX Health Care
- Exchange
- NRIX Nasdaq
- MGTX Nasdaq
- Market Cap
- NRIX 728.6M
- MGTX 670.2M
- IPO Year
- NRIX 2020
- MGTX N/A
- Fundamental
- Price
- NRIX $9.91
- MGTX $7.69
- Analyst Decision
- NRIX Strong Buy
- MGTX Strong Buy
- Analyst Count
- NRIX 15
- MGTX 2
- Target Price
- NRIX $29.13
- MGTX $24.00
- AVG Volume (30 Days)
- NRIX 733.8K
- MGTX 318.9K
- Earning Date
- NRIX 10-10-2025
- MGTX 08-14-2025
- Dividend Yield
- NRIX N/A
- MGTX N/A
- EPS Growth
- NRIX N/A
- MGTX N/A
- EPS
- NRIX N/A
- MGTX N/A
- Revenue
- NRIX $88,381,000.00
- MGTX $37,917,000.00
- Revenue This Year
- NRIX $74.59
- MGTX $145.67
- Revenue Next Year
- NRIX N/A
- MGTX $167.61
- P/E Ratio
- NRIX N/A
- MGTX N/A
- Revenue Growth
- NRIX 41.86
- MGTX 366.84
- 52 Week Low
- NRIX $8.18
- MGTX $3.86
- 52 Week High
- NRIX $29.56
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- NRIX 47.82
- MGTX 50.13
- Support Level
- NRIX $8.97
- MGTX $7.15
- Resistance Level
- NRIX $9.68
- MGTX $7.75
- Average True Range (ATR)
- NRIX 0.55
- MGTX 0.38
- MACD
- NRIX 0.04
- MGTX -0.02
- Stochastic Oscillator
- NRIX 55.13
- MGTX 42.19
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.